Gene Therapy of Inherited Retinopathies: A Long and Successful Road from Viral Vectors to Patients
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Inherited retinopathies (IRs) are common and untreatable blinding conditions inherited mostly as monogenic due to mutations in genes expressed in retinal photoreceptors (PRs) and in retinal pigment epithelium (RPE). Over the last two decades, the retina has emerged as one of the most favorable target tissues for gene therapy given its small size and its enclosed and immune-privileged environment. Different types of viral vectors have been developed, especially those based on the adeno-associated virus (AAV), which efficiently deliver therapeutic genes to PRs or RPE upon subretinal injections. Dozens of successful proofs of concept of the efficacy of gene therapy for recessive and dominant IRs have been generated in small and large models that have paved the way to the first clinical trials using AAV in patients with Leber congenital amaurosis, a severe form of childhood blindness. The results from these initial trials suggest that retinal gene therapy with AAV is safe in humans, that vision can be improved in patients that have suffered from severe impairment of visual function, in some cases for decades, and that readministration of AAV to the subretinal space is feasible, effective, and safe. However, none of the trials could match the levels of efficacy of gene therapy observed in a dog model of the disease, suggesting that there is room for improvement. In conclusion, these results bode well for further testing of AAV-mediated retinal gene therapy in patients with other monogenic and complex forms of blindness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 6×
“…NCT00516477, NCT00481546) by SR delivery of AAV2/2 encoding for the human RPE65 gene (Bainbridge et al., 2008; Cideciyan et al., 2008, 2009a,b; Hauswirth et al., 2008; Maguire et al., 2008, 2009; Simonelli et al., 2010; Ashtari et al., 2011; Bennett et al., 2012; Jacobson et al., 2012) (Table 1).”
BackgroundMethodInfluentialSelf-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 3×
“NCT006543747 Bainbridge et al., 2008.”
BackgroundGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 14×
“In fact, a clinical trial (NCT01014052) that evaluates the efficacy of systemic administration of substitute chromophores to LCA2 patients has been recently initiated, and the preliminary efficacy results are encouraging (Cideciyan et al., 2012).”
BackgroundResultInfluentialEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 5×
“In two cases, the reduced nystagmus allowed the measurement of electrical responses from the treated area by the sensitive multifocal ERG technique (Maguire et al., 2009) (Table 1).”
MethodInfluentialSelf-citationLeber congenital amaurosis: Genes, proteins and disease mechanisms
den Hollander, A. I., Roepman, R., Koenekoop, R. K., & Cremers, F. P. M. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.003 · Cited by 811 · cited 1×
“The most frequent and severe forms of IR are retinitis pigmentosa (RP) (Hartong et al., 2006), Leber congenital amaurosis (LCA) (den Hollander et al., 2008), Stargardt’s disease (STGD) (Fishman, 2010), and achromatopsia (Berger et al., 2010).”
BackgroundZhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · cited 3×
“…et al., 2001; Lotery et al., 2003; Allocca et al., 2007; Mussolino et al., 2011a); and (iii) the generation of tyrosine-mutated AAV capsids (Zhong et al., 2008b) that avoid targeting of AAVs to the proteasome, thus increasing the vector load that reaches the nucleus, resulting in increased…”
BackgroundEmerging biological roles for erythropoietin in the nervous system
Brines, M., & Cerami, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1687 · Cited by 523
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515 · cited 1×
“The first limitation can be circumvented by using self-complementary (sc) AAV vectors that package double-stranded AAV genomes (McCarty, 2008). scAAV2/2, 2/8, and 2/5 drive faster onset and stronger levels of transgene expression than their single-stranded counterparts in the retina of mice (Yokoi…”
BackgroundNew recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · cited 2×
“, 2012), the issue of insertional mutagenesis is being addressed through the generation of nonintegrating LVs (Yanez-Munoz et al., 2006), whereas vector replication and mobilization are being tackled through the use of nonprimate LVs (Pauwels et al.”
BackgroundGrieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398 · cited 1×
“…Y444,500,730F) and 2/8-Y733F determine stronger and more widespread transduction than their wild type (wt) counterparts when delivered SR in mice (Petrs-Silva et al., 2009); and (ii) quadruple and pentuple tyrosine-mutant AAV2/2 vectors are capable of transducing murine PRs and RPE when injected…”
BackgroundPhotoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy
Bennett, J., Tanabe, T., Sun, D., Zeng, Y., Kjeldbye, H., Gouras, P., & Maguire, A. M. (1996) · Nature Medicine · doi:10.1038/nm0696-649 · Cited by 316
Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292
Self-citationCorrection of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk
Vollrath, D., Feng, W., Duncan, J. L., Yasumura, D., D'Cruz, P. M., Chappelow, A., Matthes, M. T., Kay, M. A., & LaVail, M. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221364198 · Cited by 290 · cited 5×
“Consistent with these observations, the SR delivery of LVs to the adult retina was effective in rodent models of IR caused by mutations in genes expressed in the RPE (Vollrath et al., 2001; Bemelmans et al., 2006), whereas perinatal (Takahashi et al.”
BackgroundResultInfluentialNovel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267
Duan, D., Yue, Y., & Engelhardt, J. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0456 · Cited by 262 · cited 2×
“trans-splicing, overlapping, or hybrid dual-vector strategies) (Duan et al., 2001; Ghosh et al., 2008) or on packaging of oversized genomes (Grieger and Samulski, 2005; Allocca et al.”
BackgroundLeber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy
Cideciyan, A. V. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.002 · Cited by 256
Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors
Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., Vandenberghe, L. H., Wilson, J. M., Marigo, V., Surace, E. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01327-07 · Cited by 246
Self-citationZhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232 · cited 3×
“…et al., 2001; Lotery et al., 2003; Allocca et al., 2007; Mussolino et al., 2011a); and (iii) the generation of tyrosine-mutated AAV capsids (Zhong et al., 2008b) that avoid targeting of AAVs to the proteasome, thus increasing the vector load that reaches the nucleus, resulting in increased…”
BackgroundCharacterization of Genome Integrity for Oversized Recombinant AAV Vector
Dong, B., Nakai, H., & Xiao, W. (2010) · Molecular Therapy · doi:10.1038/mt.2009.258 · Cited by 230 · cited 2×
“, 2008), but contain highly heterogeneous genomes (Dong et al., 2010; Hirsch et al., 2010; Lai et al., 2010; Wu et al., 2010), which limit their use in clinical settings.”
BackgroundIntravitreal injection of AAV2 transduces macaque inner retina
Yin, L., Greenberg, K., Hunter, J. J., Dalkara, D., Kolstad, K. D., Masella, B. D., Wolfe, R., Visel, M., Stone, D., Libby, R. T., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6250 · Cited by 212 · cited 1×
“Indeed, the IV delivery of wt AAV2/2 in mice and NHPs allows transduction of the inner retina (Auricchio et al., 2001; Yin et al., 2011) and only a few scattered foveal cones (Wadsworth, 2012).”
BackgroundLaVail, M. M., Yasumura, D., Matthes, M. T., Drenser, K. A., Flannery, J. G., Lewin, A. S., & Hauswirth, W. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210319397 · Cited by 203 · cited 2×
“Allele-dependent approaches have used AAV-mediated delivery of either mutation-specific ribozymes (Lewin et al., 1998; LaVail et al., 2000) or shorthairpin (sh) RNAs (Tessitore et al., 2006) directed to the common P23H-RHO mutation.”
BackgroundBainbridge, J., Stephens, C., Parsley, K., Demaison, C., Halfyard, A., Thrasher, A., & Ali, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301574 · Cited by 197 · cited 3×
“Most studies showed that following SR delivery, LVs transduce the RPE efficiently in rodents (Auricchio et al., 2001; Bainbridge et al., 2001; Duisit et al., 2002; Kachi et al., 2009), but PRs variably and inadequately (Miyoshi et al., 1997; Bemelmans et al., 2005; Balaggan et al., 2006).”
BackgroundEvidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb
Lai, Y., Yue, Y., & Duan, D. (2010) · Molecular Therapy · doi:10.1038/mt.2009.256 · Cited by 166
Ghosh, A., Yue, Y., Lai, Y., & Duan, D. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300322 · Cited by 161
Natkunarajah, M., Trittibach, P., McIntosh, J., Duran, Y., Barker, S. E., Smith, A. J., Nathwani, A. C., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303074 · Cited by 138 · cited 1×
“…drive faster onset and stronger levels of transgene expression than their single-stranded counterparts in the retina of mice (Yokoi et al., 2007; Natkunarajah et al., 2008; Kong et al., 2010) and dogs (Petersen-Jones et al., 2009), theoretically allowing the delivery of lower vector doses to…”
BackgroundBatten, M. L., Imanishi, Y., Tu, D. C., Doan, T., Zhu, L., Pang, J., Glushakova, L., Moise, A. R., Baehr, W., Van Gelder, R. N., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020333 · Cited by 134 · cited 4×
“Gene replacement has been successfully evaluated in additional rodent models of IR caused by mutations in genes expressed in the RPE, such as MER tyrosine kinase (Mertk) (Vollrath et al., 2001; Smith et al., 2003; Tschernutter et al., 2005) and lecithin-retinol acyltransferase (LRAT) (Batten et al., 2005).”
InfluentialNovel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
Self-citationLotery, A. J., Yang, G. S., Mullins, R. F., Russell, S. R., Schmidt, M., Stone, E. M., Lindbloom, J. D., Chiorini, J. A., Kotin, R. M., & Davidson, B. L. (2003) · Human Gene Therapy · doi:10.1089/104303403322542301 · Cited by 107 · cited 1×
“…(Vandenberghe et al., 2011); (ii) the availability of AAV2/7, 2/9, and 2/5 as alternatives to AAV2/8 for PR transduction (Auricchio et al., 2001; Lotery et al., 2003; Allocca et al., 2007; Mussolino et al., 2011a); and (iii) the generation of tyrosine-mutated AAV capsids (Zhong et al., 2008b)…”
BackgroundImmune Responses Limit Adenovirally Mediated Gene Expression in the Adult Mouse Eye
Reichel, M., Ali, R., Thrasher, A., Hunt, D., Bhattacharya, S., & Baker, D. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300691 · Cited by 106
AAV-mediated photoreceptor transduction of the pig cone-enriched retina
Mussolino, C., della Corte, M., Rossi, S., Viola, F., Di Vicino, U., Marrocco, E., Neglia, S., Doria, M., Testa, F., Giovannoni, R., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.3 · Cited by 102
Self-citationReich, S. J., Auricchio, A., Hildinger, M., Glover, E., Maguire, A. M., Wilson, J. M., & Bennett, J. (2003) · Human Gene Therapy · doi:10.1089/10430340360464697 · Cited by 96 · cited 1×
“On the other hand, the efficiency of the dual AAV systems for gene delivery to the retina still remains to be thoroughly exploited, because few studies have been performed to date (Reich et al., 2003).”
BackgroundSelf-citationRPE65 Gene Delivery Restores Isomerohydrolase Activity and Prevents Early Cone Loss in Rpe65−/−Mice
Chen, Y., Moiseyev, G., Takahashi, Y., & Ma, J.-X. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0965 · Cited by 80 · cited 1×
“Despite this limitation, several studies reported that Ad-mediated gene transfer provided short-term improvements in IR animal models (Bennett et al., 1996, 1998; Kumar-Singh and Farber, 1998; Akimoto et al., 1999; Vollrath et al., 2001; Chen et al., 2006).”
BackgroundDuisit, G., Conrath, H., Saleun, S., Folliot, S., Provost, N., Cosset, F.-L., Sandrin, V., Moullier, P., & Rolling, F. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0690 · Cited by 79
Anand, V., Duffy, B., Yang, Z., Dejneka, N. S., Maguire, A. M., & Bennett, J. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0525 · Cited by 69 · cited 2×
“…et al. (2012) have successfully readministered AAV2/ 2-RPE65 to the contralateral eye of three LCA2 patients previously treated with the same vector and have observed that this is safe and effective (Table 1), confirming the immune-privileged status of the subretinal space (Anand et al., 2002).”
BackgroundChanges in adeno-associated virus-mediated gene delivery in retinal degeneration
Kolstad, K. D., Dalkara, D., Guerin, K., Visel, M., Hoffmann, N., Schaffer, D. V., & Flannery, J. G. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.194 · Cited by 63 · cited 1×
“However, if the retinal architecture is altered by a degenerative process, the diffusion of AAV viral particles to the outer retina from the vitreous side is enhanced (Park et al., 2009; Kolstad et al., 2010).”
BackgroundOcular gene transfer with self-complementary AAV vectors
Yokoi, K., Kachi, S., Zhang, H. S., Gregory, P. D., Spratt, S. K., Samulski, R. J., & Campochiaro, P. A. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-1306 · Cited by 58
Cited by
Microglia in Retinal Degeneration
Rashid, K., Akhtar-Schaefer, I., & Langmann, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01975 · Cited by 355
A novel cationic niosome formulation for gene delivery to the retina
Puras, G., Mashal, M., Zárate, J., Agirre, M., Ojeda, E., Grijalvo, S., Eritja, R., Diaz-Tahoces, A., Martínez Navarrete, G., Avilés-Trigueros, M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.11.004 · Cited by 164
Carvalho, L. S., Xiao, R., Wassmer, S. J., Langsdorf, A., Zinn, E., Pacouret, S., Shah, S., Comander, J. I., Kim, L. A., Lim, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.154 · Cited by 63
Lohia, A., Sahel, D. K., Salman, M., Singh, V., Mariappan, I., Mittal, A., & Chitkara, D. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.02.001 · Cited by 33
Chaanine, A. H., Nonnenmacher, M., Kohlbrenner, E., Jin, D., Kovacic, J. C., Akar, F. G., Hajjar, R. J., & Weber, T. (2014) · Gene Therapy · doi:10.1038/gt.2014.7 · Cited by 25
Metadata
- Authors
- Colella, P., & Auricchio, A.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2012-08
- Volume
- 23
- Issue
- 8
- Pages
- 796-807
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2093664801
- Cited by
- 50
- References
- 41
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.